• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 316
  • 295
  • 41
  • 40
  • 18
  • 10
  • 6
  • 5
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • Tagged with
  • 846
  • 846
  • 316
  • 296
  • 284
  • 216
  • 215
  • 181
  • 121
  • 120
  • 86
  • 77
  • 75
  • 65
  • 61
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
101

Combining Erythropoietin Infusion With Intramyocardial Delivery of Bone Marrow Cells Is More Effective for Cardiac Repair

Zhang, Dingguo, Zhang, Fumin, Zhang, Yuqing, Gao, Xiang, Li, Chuanfu, Yang, Naiquan, Cao, Kejiang 01 February 2007 (has links)
We postulated that combining erythropoietin (EPO) infusion with bone marrow mesenchymal stem cells (MSC) delivery may give better prognosis in a rat infarcted heart. Acute myocardial infarction (MI) model was developed by coronary artery ligation. Animals were grouped (n = 18) to receive intramyocardial injection of 30 μl saline solution without cells (EPO and control groups) or with 3 × 106 MSC from transgenic green fluorescent protein (GFP)+ male mice (MSC and MSC-EPO groups). The animals received either 5000 U/kg body weight EPO (EPO and MSC-EPO groups) or saline solution (MSC and control groups) for 7 days after MI. Cardiac functions were measured by echocardiography and cardiac tissue was harvested for immunohistological studies 3 weeks after surgery. We observed regeneration of MSC in and around the infarcted myocardium in MSC and MSC-EPO groups. Capillary density was markedly enhanced with significantly smaller infarct size and reduced fibrotic area in MSC-EPO group as compared with other three groups. A smaller left ventricular (LV) diastolic dimension and a higher LV fractional shortening were observed in MSC-EPO group than in other three groups. Transplantation of MSC combined with cytokine EPO is superior to either of the monotherapy approach for angiomyogenesis and cardiac function recovery.
102

Engineering human bone marrow stromal cells

Weber, Matthew Charles January 1991 (has links)
No description available.
103

Trajectory of Distress for Bone Marrow Transplant Inpatients and Validation of Jewish Hospital BMTU Distress Screening Measure

Barroquillo, Ashley D. January 2014 (has links)
No description available.
104

A POTENTIAL CONSEQUENCE OF EXCLUDING WORK-REQUIRED X-RAY EXPOSURES WHEN COMPUTING CUMULATIVE OCCUPATIONAL RADIATION DOSE AT A URANIUM ENRICHMENT PLANT

Cardarelli, John Joseph, II January 2000 (has links)
No description available.
105

Distress and Quality of Life in Bone Marrow Transplant Patients

Bautista, Maria Elizabeth January 2016 (has links)
No description available.
106

In vitro induction of mitogen responsiveness in murine bone marrow cells by neonatal murine thymus epithelium /

Sirinek, Lawrence Peter January 1981 (has links)
No description available.
107

Factors influencing the in vitro proliferation of rat bone marrow fibroblasts /

Bauldry, Sue Ann January 1985 (has links)
No description available.
108

Further evidence for the rodent bone marrow micronucleus assay acting as a sensitive predictor of the possible germ cell mutagenicity of chemicals

Brinkworth, Martin H., Ashby, J., Tinwell, H. January 2001 (has links)
No / Further evidence for the rodent bone marrow micronucleus assay acting as a sensitive predictor of the possible germ cell mutagenicity of chemicals
109

Principais indicações para o exame de medula óssea no serviço de hematologia e transplante de medula óssea do Hospital de Clínicas de Porto Alegre

Poletto, Karine January 2010 (has links)
O Exame de Medula Óssea (EMO) permite avaliação citológica da medula, sendo útil no diagnóstico e monitoramento de desordens hematológicas, quando exames mais simples não são suficientes para esclarecer o quadro clínico. Investigação clínica e laboratorial completa deve ser realizada para garantir que a indicação apropriada exista. São requeridas pelo menos duas colorações (Romanowsky e Azul da Prússia), onde devem ser avaliadas a qualidade da amostra, celularidade global da mesma, contagem diferencial de células nucleadas, relação Mielóide/Eritróide bem como cuidadosa avaliação quantitativa e qualitativa das três linhagens hematopoéticas (Granulocítica, Eritróide e Megacariocítica). O EMO fornece informações relevantes no diagnóstico e monitoramento de Leucemias/Linfomas, Mieloma Múltiplo (MM), Síndrome Mielodisplásica (SMD), Aplasia medular, doença metastática na Medula Óssea (MO), infecções em HIV positivos, febre de origem desconhecida e investigação de citopenias. Tendo em vista a classificação da OMS de 2008 para neoplasias mielóides e leucemias agudas cabe ressaltar a importância de unir achados citogenéticos, dentre os quais se destacam atualmente as mutações gênicas FLT3, KIT, NPM1 e CEBPA, aos achados morfológicos, imunofenotípicos, citoquímicos e clínicos, alcançando desta forma marcadores diagnósticos e prognósticos precisos que servem como guia para um tratamento eficaz. Este estudo tem por objetivo identificar as principais indicações para o EMO no HCPA bem como verificar a acurácia das mesmas. Foram analisados 400 pacientes submetidos ao EMO na Unidade de Hematologia do HCPA no período de Janeiro a Dezembro de 2009, tendo sido resgatados todos os resultados do Aspirado de Medula Óssea bem como dados clínicos e laboratoriais relevantes obtidos do prontuário médico. Verificou-se que cerca de metade dos pacientes submetidos ao EMO em nosso centro são para controle de tratamento, o que está de acordo com as características do mesmo, o qual é referência regional para tratamento de doenças malignas. Nos pacientes que realizam o exame com propósito diagnóstico as indicações principais são suspeita de Leucemia e MM. Nos 260 pacientes com suspeita de doença hematológica primária observou-se confirmação da mesma em 61% dos casos, nos 39% restantes foram encontradas alterações qualitativas e/ou quantitativas (29%), MO normal (7%) e amostra insuficiente/diluída (3%). Dos pacientes que fizeram o exame com propósito diagnóstico 20.5% não fizeram biópsia. Com relação à acurácia da indicação, encontrou-se que 7 pacientes (2%) provavelmente não deveriam ter sido submetidos a este procedimento. Ressaltamos a importância de realizar em todos os casos Aspirado e Biópsia de MO simultaneamente uma vez que seus achados devem ser correlacionados e se a Biópsia for omitida o patologista pode não obter a informação máxima requerida. / The Bone Marrow Examination (BME) permits cytological assessment of Marrow, being useful in the diagnosis and monitoring of hematological disorders, when simpler tests are not sufficient to clarify the clinical picture. Are required at least two colors (Romanowsky and Prussian blue), it should be evaluated the quality of the sample, the same overall cellularity, differential count of nucleated cells, myeloid:erythroid (M:E) ratio and carefull evaluation quantitative / qualitative from the three lineages of hematopoietic (granulocytic, erythrocytic and megakaryocytic). The BME provides information relevant to diagnosis and follow-up of leukemia/lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), marrow aplasia, bone marrow (BM) metastatic disease , infections in HIV positive, pyrexia of unknown origin and investigation of cytopenias. The 2008 classification of the World Health Organization (WHO) to the myeloid neoplasms and acute leukemia highlight the importance of join cytogenetic findings - bring out currently FLT3, KIT, NPM1 and CEBPA gene mutations - to the morphologic, immunophenotypic, cytochemical and clinical findings reaching this way accurate diagnostic and prognostic markers that serve as a guide to effective treatment. This study aims to identify the main indications for the BME at HCPA and to verify their accuracy. It were analyzed 400 patients submitted to BME in the Hematology Unit of HCPA in the period January to December 2009, having been rescued the bone marrow aspirate results as well as all relevant clinical and laboratory data obtained from the medical records. It was found that about half of patients submit BME in our center are to control treatment, which agrees with the characteristics of it, it is a regional referral center for treatment of malignancies. In patients who perform the test with diagnostic purpose the main indications were suspected leukemia and MM. In 260 patients with suspected primary hematological disease 61.2% turned out to be the case, the remaining 38.8% had quantitative and/or qualitative BM alterations (29.6%), normal MO (6.5%) and insufficient sample or diluted (2.7%). Of the patients who took the exam with diagnostic purpose 20.5% had no biopsy. With respect to accuracy of indication, it was found that 7 patients (2%) probably should not have undergone this procedure. We emphasize the importance of performing in all cases aspirate and biopsy since their findings must be correlated and furthermore if the biopsy is omitted the pathologist can not get the maximum information required.
110

The impact of family functioning on children's adaptation during a parent's bone marrow transplantation

Spath, Mary L. January 2010 (has links)
Thesis (Ph.D.)--Indiana University, 2010. / Title from screen (viewed on April 8, 2010). School of Nursing, Indiana University-Purdue University Indianapolis (IUPUI). Advisor(s): Betsy L. Fife, Joan K. Austin, Patrick O. Monahan, Silvia M. Bigatti, Linda G. Bell. Includes vitae. Includes bibliographical references (leaves 233-248).

Page generated in 0.0511 seconds